ECCO2017: European Cancer Congress

login
My congress planner

EORTC

European Organisation for Research and Treatment of Cancer

ECCO 2017 – EORTC Session

register now

27 January 2017

SESSION 1: The regulatory and methodological dimensions of long term efficacy: PFS2 and looking beyond the first progression (13.00 - 14.50)
Jan Bogaerts (Chair)

  • 13.00 - 13.20: The regulator’s view on the PFS 2 endpoint, and recommendations for definition and analysis (J. Camarero)
  • 13.20 - 13.40: The clinician's view on the PFS 2 endpoint, Part 1 (E. Eisenhauer)
  • 13.40 - 14.00: The clinician's view on the PFS 2 endpoint, Part 2 (S. Sleijfer)
  • 14.00 - 14.20: The statistician’s view on definition and analysis recommendations for PFS 2 as a comparative endpoint (L. Collette)
  • 14.20 - 14.50: Panel discussion

 

COFFEE BREAK (14.50 - 15.20)

 

SESSION 2: Towards real life – Registry- external validity of clinical trials (15.00 -16:45)
Lifang Liu (Chair)

  • 15.20 - 15.40: Do patients included in clinical trials represent the real-world patient population?-An evaluation of EORTC boost-no-boost trial (22881-10882) using the Dutch Cancer Registry data (S. Siesling)
  • 15.40 - 16.00: Do practice-changing trials change practice in real-world? A case study looking at implementation of findings from the EORTC 22931 on head and neck cancer (H. de Schutter)
  • 16.00 - 16.20: Discrepancies in long-term survival and quality of life among Hodgkin’s Lymphoma patients treated inside and outside of clinical trials, EORTC H1-H9 trials linked with Dutch Cancer Registry (L. Liu)
  • 16.20 - 16.45: Panel discussion “Way forward-ideas, methods, and expected outcomes”
    Panel: G. Gatta (IT)

 

WRAP-UP:

  • 16.45 - 17.00: Wrap-up: The impact of new methods on EORTC’s research
PRINT THIS PAGE Page last modified: